{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:33:46Z","timestamp":1784691226013,"version":"3.55.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"8-9","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.neurol.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T20:50:44Z","timestamp":1469825444000},"page":"446-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Gilles de la Tourette syndrome\u00a0\u2013\u00a0A treatable condition?"],"prefix":"10.1016","volume":"172","author":[{"given":"A.","family":"Hartmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2016.07.004_bib0400","series-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"10.1016\/j.neurol.2016.07.004_bib0405","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/jamapsychiatry.2014.2650","article-title":"Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome","volume":"72","author":"Hirschtritt","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.004_bib0410","series-title":"Tourette syndrome","author":"Martino","year":"2013"},{"key":"10.1016\/j.neurol.2016.07.004_bib0415","article-title":"Advances in the neurochemistry and neuropharmacology of Tourette syndrome","volume":"Vol.\u00a0112","author":"Martino","year":"2013"},{"key":"10.1016\/j.neurol.2016.07.004_bib0420","first-page":"158","article-title":"\u00c9tude sur une affection nerveuse caract\u00e9ris\u00e9e par de l\u2019incoordination motrice accompagn\u00e9e d\u2019\u00e9cholalie et de coprolalie","volume":"9","author":"Gilles de La Tourette","year":"1885","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0425","series-title":"A cursing brain? The histories of Tourette syndrome","author":"Kushner","year":"2000"},{"key":"10.1016\/j.neurol.2016.07.004_bib0430","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.neubiorev.2012.10.014","article-title":"Pharmacological treatment of Gilles de la Tourette syndrome","volume":"37","author":"Hartmann","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.neurol.2016.07.004_bib0435","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10597-011-9465-y","article-title":"The impact of Tourette syndrome in adults: results from the Tourette syndrome impact survey","volume":"49","author":"Conelea","year":"2013","journal-title":"Community Ment Health J"},{"issue":"4","key":"10.1016\/j.neurol.2016.07.004_bib0440","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00787-011-0164-6","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment","volume":"20","author":"Cath","year":"2011","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.neurol.2016.07.004_bib0445","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00787-011-0163-7","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment","volume":"20","author":"Roessner","year":"2011","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.neurol.2016.07.004_bib0450","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00787-011-0167-3","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions","volume":"20","author":"Verdellen","year":"2011","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.neurol.2016.07.004_bib0455","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00787-011-0166-4","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation","volume":"20","author":"M\u00fcller-Vahl","year":"2011","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.004_bib0460","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40474-015-0063-5","article-title":"Behavior therapy for tic disorders: an evidenced-based review and new directions for treatment research","volume":"2","author":"McGuire","year":"2015","journal-title":"Curr Dev Disord Rep"},{"key":"10.1016\/j.neurol.2016.07.004_bib0465","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0005-7967(73)90119-8","article-title":"Habit-reversal: a method of eliminating nervous habits and tics","volume":"11","author":"Azrin","year":"1973","journal-title":"Behav Res Ther"},{"key":"10.1016\/j.neurol.2016.07.004_bib0470","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.2010.607","article-title":"Behavior therapy for children with Tourette disorder: a randomized controlled trial","volume":"303","author":"Piacentini","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2016.07.004_bib0475","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/archgenpsychiatry.2011.1528","article-title":"Randomized trial of behavior therapy for adults with Tourette syndrome","volume":"69","author":"Wilhelm","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.004_bib0480","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0005-7967(03)00154-2","article-title":"Exposure with response prevention versus habit reversal in Tourettes's syndrome: a controlled study","volume":"42","author":"Verdellen","year":"2004","journal-title":"Behav Res Ther"},{"key":"10.1016\/j.neurol.2016.07.004_bib0485","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0005-7967(00)00048-6","article-title":"Evaluation of a cognitive-behavioural program for the management of chronic tic and habit disorders","volume":"39","author":"O\u2019Connor","year":"2001","journal-title":"Behav Res Ther"},{"key":"10.1016\/j.neurol.2016.07.004_bib0490","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.neuropsychologia.2015.05.024","article-title":"Cognitive-behavioral therapy induces sensorimotor and specific electrocortical changes in chronic tic and Tourette's disorder","volume":"79","author":"Morand-Beaulieu","year":"2015","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neurol.2016.07.004_bib0495","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/070674371405900804","article-title":"Meta-cognitions in Tourette syndrome, tic disorders, and body-focused repetitive disorder","volume":"59","author":"O\u2019Connor","year":"2014","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.004_bib0500","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1891\/0889-8391.26.1.57","article-title":"Psychosocial treatment to improve resilience and reduce impairment in youth with tics: an intervention case series of eight youth","volume":"26","author":"Storch","year":"2012","journal-title":"J Cogn Psychother"},{"key":"10.1016\/j.neurol.2016.07.004_bib0505","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.psychres.2014.11.045","article-title":"Living with tics: reduced impairment and improved quality of life for youth with chronic tic disorders","volume":"225","author":"McGuire","year":"2015","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.neurol.2016.07.004_bib0510","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/YCO.0b013e328358e531","article-title":"The third wave of cognitive behavioural therapies: what is new and what is effective?","volume":"25","author":"Kahl","year":"2012","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.004_bib0515","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jpsychores.2014.08.001","article-title":"Mindfulness-based stress reduction for Tourette syndrome and chronic tic disorder: a pilot study","volume":"78","author":"Reese","year":"2015","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.neurol.2016.07.004_bib0520","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10882-010-9221-1","article-title":"Habit reversal training and acceptance and commitment therapy for Tourette syndrome: a pilot project","volume":"23","author":"Franklin","year":"2011","journal-title":"J Dev Phys Disabil"},{"key":"10.1016\/j.neurol.2016.07.004_bib0525","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.brat.2012.05.009","article-title":"A randomized pilot trial comparing videoconference versus face-to-face delivery of behavior therapy for childhood tic disorders","volume":"50","author":"Himle","year":"2012","journal-title":"Behav Res Ther"},{"key":"10.1016\/j.neurol.2016.07.004_bib0530","article-title":"A randomized waitlist-controlled pilot trial of voice over Internet protocol-delivered behavior therapy for youth with chronic tic disorders","author":"Ricketts","year":"2015","journal-title":"J Telemed Telecare"},{"key":"10.1016\/j.neurol.2016.07.004_bib0535","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5014\/ajot.2013.007062","article-title":"Comprehensive behavioral intervention to improve occupational performance in children with Tourette disorder","volume":"67","author":"Rowe","year":"2013","journal-title":"Am J Occup Ther"},{"key":"10.1016\/j.neurol.2016.07.004_bib0540","article-title":"Pilot testing behavior therapy for chronic tic disorders in neurology and developmental pediatrics clinics","author":"Ricketts","year":"2015","journal-title":"J Child Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0545","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/070674371205700302","article-title":"Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy","volume":"57","author":"Pringsheim","year":"2012","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.004_bib0550","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejpn.2011.12.001","article-title":"Treatment practices in Tourette syndrome: the European perspective","volume":"16","author":"Rickards","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0555","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/mds.23894","article-title":"Does Tourette syndrome prevent tardive dyskinesia?","volume":"26","author":"M\u00fcller-Vahl","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.004_bib0560","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/B978-0-12-411546-0.00011-1","article-title":"Clinical pharmacology of nondopaminergic drugs in Tourette syndrome","volume":"112","author":"Hartmann","year":"2013","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0565","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.neubiorev.2012.09.008","article-title":"Systematic review: pharmacological treatment of tic disorders\u00a0\u2013\u00a0efficacy of antipsychotic and alpha-2 adrenergic agonist agents","volume":"37","author":"Weisman","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.neurol.2016.07.004_bib0570","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hup.2495","article-title":"Serial pharmacological prescribing practices for tic management in Tourette syndrome","volume":"30","author":"Farag","year":"2015","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0575","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2152\/jmi.52.284","article-title":"Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist","volume":"52","author":"Hirose","year":"2005","journal-title":"J Med Invest"},{"key":"10.1016\/j.neurol.2016.07.004_bib0795","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.4088\/JCP.12m08189","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder","volume":"74","author":"Yoo","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.004_bib0585","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1089\/cap.2011.0081","article-title":"Aripiprazole in children with Tourette's disorder and co-morbid attention-deficit\/hyperactivity disorder: a 12-week, open-label, preliminary study","volume":"22","author":"Masi","year":"2012","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0590","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pediatrneurol.2012.08.015","article-title":"Metabolic effects of aripiprazole and pimozide in children with Tourette syndrome","volume":"47","author":"Rizzo","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0595","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/WNF.0000000000000017","article-title":"A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome","volume":"37","author":"Gilbert","year":"2014","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0600","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","article-title":"A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome","volume":"81","author":"Jankovic","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.004_bib0605","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.parkreldis.2009.11.011","article-title":"Botulinum toxin type A in simple motor tics: short-term and long-term treatment-effects","volume":"16","author":"Rath","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2016.07.004_bib0610","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2013\/294264","article-title":"Treatment of Tourette syndrome with cannabinoids","volume":"27","author":"M\u00fcller-Vahl","year":"2013","journal-title":"Behav Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0615","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2016.07.004_bib0620","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/mds.26089","article-title":"Population prevalence of Tourette syndrome: a systematic review and meta-analysis","volume":"30","author":"Scharf","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.004_bib0625","doi-asserted-by":"crossref","first-page":"13307","DOI":"10.1073\/pnas.0502624102","article-title":"Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome","volume":"102","author":"Kalanithi","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2016.07.004_bib0630","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cne.22206","article-title":"Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome","volume":"518","author":"Kataoka","year":"2010","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0635","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clinthera.2008.01.010","article-title":"Donepezil use in children and adolescents with tics and attention-deficit\/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study","volume":"30","author":"Cubo","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.neurol.2016.07.004_bib0640","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mds.26210","article-title":"Altered cholinergic neurotransmission in Tourette syndrome","volume":"30","author":"Ganos","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.004_bib0645","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/jne.12066","article-title":"The implication of neuroactive steroids in Tourette's syndrome pathogenesis: a role for 5\u03b1-reductase?","volume":"25","author":"Bortolato","year":"2013","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0650","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/mds.23810","article-title":"A preliminary study of finasteride in Tourette syndrome","volume":"26","author":"Muroni","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.004_bib0655","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.mehy.2009.11.028","article-title":"Glutamatergic modulatory therapy for Tourette syndrome","volume":"74","author":"Singer","year":"2010","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.neurol.2016.07.004_bib0660","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pediatrneurol.2015.02.002","article-title":"Efficacy of glutamate modulators in tic suppression: a double-blind, randomized control trial of D-serine and riluzole in Tourette syndrome","volume":"52","author":"Lemmon","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0665","first-page":"203","article-title":"Histaminergic modulation in Tourette syndrome","volume":"4","author":"Cox","year":"2016","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.neurol.2016.07.004_bib0670","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1056\/NEJMoa0907006","article-title":"L-histidine decarboxylase and Tourette's syndrome","volume":"362","author":"Ercan-Sencicek","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2016.07.004_bib0675","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/jmedgenet-2013-101637","article-title":"Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families","volume":"50","author":"Karagiannidis","year":"2013","journal-title":"J Med Genet"},{"key":"10.1016\/j.neurol.2016.07.004_bib0680","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuron.2013.10.052","article-title":"Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humansand mice","volume":"81","author":"Castellan Baldan","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neurol.2016.07.004_bib0685","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","article-title":"Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial","volume":"12","author":"Dauvilliers","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0690","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00415-011-6171-1","article-title":"Increasing histamine neurotransmission in Gilles de la Tourette syndrome","volume":"259","author":"Hartmann","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0695","article-title":"Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions","author":"Rapanelli","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurol.2016.07.004_bib0700","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.26094","article-title":"Tourette syndrome deep brain stimulation: a review and updated recommendations","volume":"30","author":"Schrock","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.004_bib0705","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5334\/tohm.126","article-title":"Lessons learned from open-label deep brain stimulation for Tourette syndrome: eight cases over 7 years","author":"Motlagh","year":"2013","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"10.1016\/j.neurol.2016.07.004_bib0710","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3171\/JNS-07\/11\/1004","article-title":"Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in adults with Tourette syndrome","volume":"107","author":"Maciunas","year":"2007","journal-title":"J Neurosurg"},{"key":"10.1016\/j.neurol.2016.07.004_bib0715","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/brain\/awq380","article-title":"Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome","volume":"134","author":"Ackermans","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2016.07.004_bib0720","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(15)00008-3","article-title":"Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial","volume":"14","author":"Kefalopoulou","year":"2015","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.neurol.2016.07.004_bib0725","doi-asserted-by":"crossref","first-page":"e104926","DOI":"10.1371\/journal.pone.0104926","article-title":"Deep brain stimulation of the antero-medial globus pallidus interna for Tourette syndrome","volume":"9","author":"Sachdev","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2016.07.004_bib0730","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00415-009-5159-6","article-title":"De novo and rescue DBS leads for refractory Tourette syndrome patients with severe comorbid OCD: a multiple case report","volume":"256","author":"Servello","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0735","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1227\/NEU.0000000000001004","article-title":"Deep brain stimulation in Gilles de la Tourette syndrome: what does the future hold? A cohort of 48 patients","volume":"78","author":"Servello","year":"2016","journal-title":"Neurosurgery"},{"key":"10.1016\/j.neurol.2016.07.004_bib0740","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00701-012-1497-8","article-title":"Deep brain stimulation for treatment of refractory Tourette syndrome: long-term follow-up","volume":"154","author":"Porta","year":"2012","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.neurol.2016.07.004_bib0745","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1525-1403.2012.00526.x","article-title":"Behavioral and motor improvement after deep brain stimulation of the globus pallidus externus in a case of Tourette's syndrome","volume":"16","author":"Piedimonte","year":"2013","journal-title":"Neuromodulation"},{"key":"10.1016\/j.neurol.2016.07.004_bib0750","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1212\/WNL.0b013e3181a60a0c","article-title":"Improvement of tics after subthalamic nucleus deep brain stimulation","volume":"72","author":"Martinez-Torres","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.07.004_bib0755","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/mds.26199","article-title":"Selective dysfunction of basal ganglia subterritories: from movement to behavioral disorders","volume":"30","author":"Tremblay","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.004_bib0760","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00701-010-0851-y","article-title":"Tourette syndrome (TS) bears a higher rate of inflammatory complications at the implanted hardware in deep brain stimulation (DBS)","volume":"153","author":"Servello","year":"2011","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.neurol.2016.07.004_bib0765","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1212\/WNL.0b013e3181bd809b","article-title":"Thalamic deep brain stimulation for treatment-refractory Tourette syndrome: two-year outcome","volume":"73","author":"Porta","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.07.004_bib0770","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1474-4422(15)00043-5","article-title":"Design challenges for stimulation trials of Tourette's syndrome","volume":"14","author":"Jimenez-Shahed","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0775","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/jamaneurol.2013.580","article-title":"A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms","volume":"70","author":"Okun","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0780","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3988\/jcn.2015.11.2.122","article-title":"Chasing tics in the human brain: development of open, scheduled and closed loop responsive approaches to deep brain stimulation for Tourette syndrome","volume":"11","author":"Almeida","year":"2015","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.neurol.2016.07.004_bib0785","doi-asserted-by":"crossref","DOI":"10.1007\/s00787-016-0823-8","article-title":"The effects of Gilles de la Tourette syndrome and other chronic tic disorders on quality of life across the lifespan: a systematic review","author":"Evans","year":"2016","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.004_bib0790","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1155\/2013\/354604","article-title":"A brief history of the European society for the study of Tourette syndrome","volume":"27","author":"Rickards","year":"2013","journal-title":"Behav Neurol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378716300170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378716300170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T10:11:56Z","timestamp":1656929516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378716300170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":79,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0035378716300170"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2016.07.004","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gilles de la Tourette syndrome\u00a0\u2013\u00a0A treatable condition?","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}